BPC-157 + TB-500 Stack vs Thymosin Alpha-1
A neutral, side-by-side comparison of two healing & recovery peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
BPC-157 + TB-500 Stack
The most widely researched peptide stack for tissue repair, combining BPC-157 (angiogenesis and growth factor upregulation) with TB-500 (actin regulation and cell migration). The two compounds address complementary and non-overlapping stages of the healing cascade, producing synergistic effects in tendon, ligament, muscle, and gut injury research models.
Full profileThymosin Alpha-1
Thymosin Alpha-1 (Tα1) is a 28-amino acid peptide naturally derived from the thymus gland. It plays a central role in regulating immune function — specifically in the maturation and differentiation of T-cells. Unlike most research peptides, Thymosin Alpha-1 has approved clinical use in multiple countries (China, Italy, and others) for hepatitis B, hepatitis C, and as an immune adjuvant in cancer patients undergoing chemotherapy. In the US it is sold as Zadaxin and used as a research compound.
Full profile| BPC-157 + TB-500 Stack | Thymosin Alpha-1 | |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| Also known as | Wolverine Stack, BPC TB500 combination, healing stack, BPC-157 TB-500 | Tα1, Thymalfasin, Zadaxin |
| Evidence | Research-stage | Research-stage |
| Dosing range | BPC-157 250mcg + TB-500 2.5mg–BPC-157 750mcg + TB-500 7.5mg varies by component, 2–3x per week | 900mcg–3.2mg mg, 2–3 times per week subcutaneously |
| Administration | Subcutaneous injection, Intramuscular injection | Subcutaneous injection |
| Key side effects | BPC-157: nausea (rare), dizziness, lightheadedness, TB-500: fatigue, headache, injection site reactions, No documented combination-specific adverse effects, Theoretical oncological considerations (angiogenesis stimulation) — relevant in cancer history | Generally very well tolerated, Mild injection site reactions (most common), Transient fatigue in initial doses, Flu-like symptoms (rare) |
| Cited sources | 2 references | 4 references |
Key differences
- Administration: BPC-157 + TB-500 Stack — Subcutaneous injection, Intramuscular injection; Thymosin Alpha-1 — Subcutaneous injection.
- Dosing units differ: BPC-157 + TB-500 Stack is dosed in varies by component, Thymosin Alpha-1 in mg — they operate at different scales.
- Frequency: BPC-157 + TB-500 Stack is typically 2–3x per week; Thymosin Alpha-1 is 2–3 times per week subcutaneously.
- Research depth: this profile cites 2 sources for BPC-157 + TB-500 Stack vs 4 for Thymosin Alpha-1.
How each works
BPC-157 + TB-500 Stack
BPC-157 and TB-500 work through entirely non-overlapping mechanisms and have been combined in numerous community protocols for injury recovery. BPC-157 drives angiogenesis and growth factor receptor expression; TB-500 regulates actin polymerization and cell migration into the injury site. No documented negative interactions exist — the combination is considered synergistic in the healing research community based on the complementary biology of each compound.
Thymosin Alpha-1
Extensive human clinical research documents Tα1's immune-modulating effects. It increases T-cell counts, enhances NK cell activity, and promotes Th1 cytokine balance. Multiple randomized trials have shown efficacy in treating chronic hepatitis B and C, reducing infection severity in critically ill patients, and improving outcomes in sepsis. More recent research investigates its role in long COVID immune dysregulation. It is considered one of the best-studied peptides in immunology.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.